DISCO Pharmaceuticals GmbH
Oncology Therapeutics · Biotechnology
Overview
The surfaceome company. Our mission is to improve patient care by unleashing the full potential of targeted cancer therapies using our transformative cell surfaceome discovery technology.
People
Mark Manfredi
Geschäftsführer
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Project Lead - Target Validation and Drug Discovery (m/w/d)
WHO WE ARE DISCO Pharmaceuticals is an emerging biotechnology company with operations in Cologne, Germany, and Schlieren, Switzerland. We leverage a proprietary mass spectrometry-based technology platform to decode the molecular architecture of the cancer
Read more
Report
Vice President Discovery (m/w/d)
WHO WE ARE DISCO Pharmaceuticals is an emerging biotechnology company with operations in Cologne, Germany, and Schlieren, Switzerland. We leverage a proprietary mass spectrometry-based technology platform to decode the molecular architecture of the cancer
Read more
Report
Vice President Antibody Engineering (m/w/d)
WHO WE ARE DISCO Pharmaceuticals is an emerging biotechnology company with operations in Cologne, Germany, and Schlieren, Switzerland. We leverage a proprietary mass spectrometry-based technology platform to decode the molecular architecture of the cancer
Read more
Report
J.P. Morgan Healthcare Conference, 2026
10-13 January 2026 J.P. Morgan Healthcare Conference, 2026 San Francisco
Read more
Report
DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies
DISCO Pharmaceuticals ("DISCO") today announced the appointment of seasoned biotech leader Mark Manfredi, Ph.D., as Chief Executive Officer (CEO), as well as the final close of a €36 million seed financing round to advance the company's pipeline of surfac
Read more
Report
Digital Pathology and AI Congress: Europe, 2025
10-11 December 2025 Digital Pathology and AI Congress: Europe, 2025 London
Read more
Report
DISCO Pharmaceuticals Appoints Mark Manfredi as CEO and Announces Final Close of €36 Million Seed Financing
DISCO Pharmaceuticals ("DISCO") today announced the appointment of seasoned biotech leader Mark Manfredi, Ph.D., as Chief Executive Officer (CEO), as well as the final close of a €36 million seed financing round to advance the company's pipeline of surfac
Read more
Report
Jefferies Global Healthcare Conference, 2025
17-20 November 2025 Jefferies Global Healthcare Conference, 2025 London
Read more
Report
Report
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Cologne
Germany
Regional office
Impressum
50-200 est. staff
Gottfried-Hagen-Str. 60 – 62, 51105 Cologne